Lv11
20 积分 2021-03-29 加入
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
6小时前
待确认
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
6小时前
已完结
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
8小时前
已完结
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
9小时前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
14天前
已完结
CAR-T therapy in solid tumors
18天前
已完结
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
18天前
已完结
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant
18天前
已完结
Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
19天前
已完结
Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
4年前
已完结
皖公网安备34019202002308
